|
Session 110
Poster Abstracts
Molecular Diagnostics
Tuesday, 1:30 - 3:30 pm
Poster Hall |
659
 |
Performance of the TRUGENE HIV-1 gp41 Analyte-specific Reagents (ASR)
Michelle Marcial*1, J Lu1, S Deeks2, R Ziermann3, and D Kuritzkes1
1Brigham and Women's Hosp, Boston, MA, US; 2Univ of California, San Francisco, US; and 3Bayer HlthCare, Berkeley, CA, US |
| 660 |
Comparison of Online Clinical Database HIV-1 Subtyping Tools
Clive Loveday* and E Macrae
ICVC Charitable Trust, Buckinghamshire, UK |
661
|
Sensitivity of the ViroSeqTM HIV-1 Genotyping System for Detection of the K103N Resistance Mutation in HIV-1 Subtypes A, C and D
Jessica D. Church*1, T Flys1, D Jones1, N Marlowe2, L Guay1, J Jackson1, N Kumwenda3, T Taha3, and S Eshleman1
1Johns Hopkins Univ Sch of Med, Baltimore, MD, US; 2Celera Diagnostics, Alameda CA US; and 3Johns Hopkins Univ, Bloomberg Sch of Publ Hlth, Baltimore, MD, US |
| 662 |
Optimization of Allele-specific PCR for Drug-resistant HIV Variants using Patient-specific Consensus Sequences for Primer Design
Sarah Palmer*1, V Boltz1, F Maldarelli1, J McIntyre2, L Morris3, M Hopley4, D Mayers5, P Robinson5, J Mellors6, and J Coffin1
1NCI, Frederick, MD, US; 2Chris Hani Baragwanath Hosp, Univ of the Witwatersrand, Johannesburg, South Africa; 3Natl Inst for Communicable Diseases, Johannesburg, South Africa; 4Boehringer Ingelheim, Johannesburg, South Africa; 5Boehringer Ingelheim Pharma, Ridgefield, CT, US; and 6Univ of Pittsburgh, PA, US |
663
|
Novel Probe Design for Real-time HIV-1 Assay for Quantitation of HIV-1 RNA in Diverse Subtypes/Groups
K Abravaya1, J Hackett2, S Huang1, W B Mak1, K C Luk2, J Salituro1, P Swanson2, and Ning Tang*1
1Abbott Molecular, Des Plaines, IL, US and 2Abbott Labs, Abbott Park, IL, US |
| 664 |
Cavidi Exavir Viral Load and Phenotype Assays
Susan Fiscus*1, A Cachafeiro1, P Stewart1, S Napravnik1, I Frank2, J Eron Jr1, and the Adult AIDS Clin Trials Group NWCS 227 Team
1Univ of North Carolina at Chapel Hill, US and 2Univ of Pennsylvania, Philadelphia, US |
665
|
Evaluation of an Automated Sample Preparation System and Real-time Assay for Quantitation of Genetically Diverse HIV-1 Specimens from Brazil
John Hackett, Jr*1, P Swanson1, V Holzmayer1, J Yamaguchi1, S Huang2, P Bodelle1, C Brennan1, R Badaro3,4, C Brites3, and S Devare1
1Abbott Labs, Abbott Park, IL, US; 2Abbott Molecular, Des Plaines, IL, US; 3Fndn Bahiana de Infectologia, Univ Federal da Bahia, Brazil; and 4Univ of California, San Diego, US |
| 666 |
Evaluation of Dried Blood Spots for HIV-1 Drug Resistance Surveillance
J Gerardo Garcia-Lerma*1, A McNulty1, C Jennings2, D Bennett1, J Fitzgibbon3, J Bremer2, M Ussery3, T Folks1, M Kalish1, and W Heneine1
1CDC, Atlanta, GA, US; 2Rush Med Coll, Chicago, IL, US; and 3NIAID, NIH, DHHS, Bethesda, MD, US |
| 667a |
Clinical Utility of HLA-B*5701 Testing in a UK Clinic Cohort
Iain Reeves*, M Fisher, and D Churchill
Brighton and Sussex Univ Hosp NHS Trust, Brighton, UK |
667b
|
Mitochondrial Dysfunction in HAART Detected with Simple Quantitative Dipstick Assays for Mitochondrial Proteins
Michael Marusich*1,2, J Willis1, R Capaldi1,2, C Shikuma3, and M Gerschenson3
1Mitosci LLC, Eugene, OR, US; 2Univ of Oregon, Eugene, US; and 3Univ of Hawaii, Honolulu, US |
|
